Sana Biotech Reports Non-Exclusive License Deal With IASO Biotherapeutics, Innovent Biologics For Clinically Validated B Cell Maturation Antigen Construct; IASO Bio, Innovent To Receive Upfront Payments, Entitled For Up To $204M In Milestones